Table of Contents
EAST WINDSOR, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for Aurobindo Receives FDA Approval for clomipramine hydrochloride capsules USP, 25mg, 50mg, and 75mg. Aurobindo Pharma’s clomipramine hydrochloride capsules, are an AB-rated generic equivalent to the reference listed drug (RLD), Anafranil Capsules, manufactured by SpecGx.
Clomipramine hydrochloride capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD).
Clomipramine hydrochloride capsules, has an estimated market size of US $18 Million for the twelve months ending April 2023, as per IQVIA.
